"Lilly has spent decades building comprehensive datasets for drug discovery. Today, we're sharing the intelligence gained from that investment to help lift the tide of biotechnology research," said Daniel Skovronsky, M.D., Ph.D., chief scientific officer, and president, Lilly Research Laboratories and Lilly Immunology.
"Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists. By opening up access, we hope to accelerate the creation of new medicines for patients who need them."
Lilly TuneLab is powered by Lilly's full drug disposition, safety, and preclinical datasets representing experimental data obtained with hundreds of thousands of unique molecules.
In return for access, selected biotech partners contribute training data, which fuels continuous improvement for the benefit of others in the ecosystem and ultimately patients.
Read more | LILLY